Current HCV Treatment:
FDA
approved medications to treat hepatitis C, side effect management, disease
progression after successful treatment, and treatment of various populations of
people with hepatitis C.
·
Disease Progression
o LB9. Sustained Virologic Response Is Associated with
Eradication of Hepatitis C Virus and Fibrosis Regression in Patients Treated
for Chronic Hepatitis C (updated November 8, 2006)
o 337. Clinical, biochemical, virologic and histologic outcomes of chronic hepatitis C following
sustained virologic response (SVR) to HCV therapy: a prospective 5 year cohort
study (updated October 28, 2006)
o 403. Improvement in immunological abnormalities in
patients with chronic hepatitis C who have a sustained virological response to
therapy (updated October 28, 2006)
·
Drug users
o 88. Integrated Drug and HCV Treatment for
Street-Recruited Heroin Users
o 370. Hepatitis C screening and treatment among drug
users in Amsterdam: interim results of the inclusion procedure in the Dutch C
project (updated October 31, 2006)
o 375. Successful hepatitis C virus eradication in
intravenous drug users maintained with subcutaneous naltrexone
implants (updated October 28, 2006)
o 396. Substitute opiate use in intravenous drug users (IVDUs) does not adversely effect sustained virological
response(SVR) following treatment of chronic hepatitis C (CHC) with pegylated
interferon alpha (PEG- IFN) and ribavirin (updated November 3,
2006)
o 399. Managing HCV infection in injecting drug users: a
community model (updated November 8, 2006)
·
General
o 247. Detection of low amounts of HCV-RNA in the serum
of sustained virological responders after antiviral therapy (updated October 28,
2006)
o 346. Evaluation of the efficacy of an 18 week short
treatment duration in HCV type 1 infected patients based upon early viral
kinetics: an approach to recognise “super-responders”
(updated
October 28, 2006)
o 351. Treatment with peg-interferon and ribavirin
therapy in dialysis patients with chronic hepatitis C (updated October 28,
2006)
o 356. Development of HCC in Patients who Achieve SVR to IFN-Based
Therapies is Associated with Cirrhosis and Prior HBV Exposure (updated November 8,
2006)
o 359. Therapy A la Carte Is More Cost-Effective Than
Standard Combination Therapy For Naive Patients With Chronic Hepatitis C
(updated
November 1, 2006)
o 361. Re-infection following successful treatment for
Hepatitis C virus Infection with either alpha interferon or pegylated
interferon/ribavirin combination therapy (updated November 3,
2006)
o 371. Pegylated interferon and ribavirin in haemodialyzed patients with chronic hepatitis C: a prospective
study (updated October 28, 2006)
o 376. Late treatment of chronic hepatitis C in renal
transplant recipients : an open pilot study (updated October 28,
2006)
o 378. Maintenance pegylated IFN given once every three
weeks prevents relapse of hepatitis C virus (HCV) in decompensated cirrhosis
(updated
October 28, 2006)
o 382. Assessment of Th1 and Th2 cytokines during
antiviral therapy for HCV Mixed Cryoglobulinemia
o 389. Antiviral therapy for HCV-associated mixed
cryoglobulinemia vasculitis : a long term follow-up (updated October 28, 2006)
o 397. Effectiveness of Antiviral Therapy in Patients
with Chronic Hepatitis C Treated in Daily Clinical Practice (updated October 28,
2006)
o 400. Pegylated interferon plus ribavirin in chronic
hepatitis C patients with liver lesions related to alcohol intake (updated October 28,
2006)
o 402. The Therapeutic Effect of Ribavirin plus Pegylated
Interferon in Chronic Hepatitis B and C
o 1126. Hepatitis C virus directly causes insulin resistance
independent of the visceral adipose tissue area in non-obese and non-diabetic
Japanese patients (disease progression – metabolic syndromes (updated October 31,
2006)
·
Infergen
o 1128. Extended Treatment of 72 versus 48 Weeks for Chronic
Hepatitis C Patients with Genotype 1 and High Viral Load using Daily Consensus
Interferon and Ribavirin (updated October 31, 2006)
o 1129. Treatment of Hepatitis C Patients with Child A and
B Cirrhosis with Consensus Interferon and Ribavirin in a Low Ascending Dosing
Regimen Leads to Significant Viral Elimination Rates (updated October 31,
2006)
·
Methadone
·
Pegasys
o 335. Improved sustained virological response (SVR)
rates with higher, fixed doses of peginterferon
alfa-2a (40KD) (PEGASYS®) plus ribavirin (RBV)(COPEGUS®) in
patients with “difficult-to-cure” characteristics. (updated November 1,
2006)
o 340. Utility of virological response at weeks 4 and 12
in the prediction of SVR rates in genotype 2/3 patients treated with peginterferon alfa-2a (40KD) plus ribavirin: findings from
ACCELERATE (updated November 1, 2006)
o 342. Effect of drug exposure on sustained virological
response (SVR) in patients with chronic hepatitis C virus genotype 2 or 3
treated with peginterferon alfa-2a (40KD) (PEGASYS®)
plus ribavirin (COPEGUS®) for 16 or 24 weeks (updated October 28,
2006)
o 350. Definition of a pre-treatment viral load cut-off
for an optimized prediction of treatment outcome in patients with genotype 1
infection receiving either 48 or 72 weeks of peginterferon
alfa-2a plus ribavirin (updated October 28, 2006)
o 353. Efficacy and safety of peginterferon
alfa-2a administrated every five days in combination with ribavirin in hcv genotype 1-infected patients with severe fibrosis not
responding to weekly administrations of peginterferon
in combination with ribavirin (updated October 31, 2006)
o 365. The PRESCO trial: impact of higher ribavirin doses
and longer duration of therapy with peginterferon
alfa-2a plus ribavirin in HIV-infected patients with chronic hepatitis C (updated November 1, 2006)
o 368. Better prediction of SVR in patients with HCV
genotype 1 (G1) with peginterferon alfa-2a (PEGASYS)
plus ribavirin: Improving differentiation between low (LVL) and high baseline
viral load (HVL) (updated October 28, 2006)
o 380. Efficacy and safety of peginterferon
alfa-2a (40KD) plus ribavirin in HCV patients with complete cirrhosis (Knodell
score F4) (updated October 28, 2006)
o 381. Effect of hepatic steatosis in patients with
chronic hepatitis C virus genotype 2 or 3 treated with peginterferon
alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for
16 or 24 weeks (updated October 28, 2006)
o 388. Exposure to ribavirin (RBV) predicts EVR and SVR
in patients with HCV genotype 1 infection: analysis of the Canadian Pegasys
Expanded Access Program (EAP) (updated November 8, 2006)
o 390. Customizing treatment with peginterferon
alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in
patients with HCV genotype 1 or 4 infection. Interim results of a prospective
randomized trial (updated November 8, 2006)
o 392. Treatment of subjects with chronic hepatitis C
infection (HCV) and end stage renal disease (ESRD) using low dose pegylated
interferon alpha 2 a (PEG-IFN) and Ribavirin (RBV) (updated November 8,
2006)
o 395. Early predictors of anemia in patients with HCV
genotype 1 treated with peginterferon alfa-2a (40KD)
plus ribavirin 1000-1200 mg/day (updated October 28, 2006)
o 1123. HCV RNA Negativity After 12 Weeks of Therapy is
the Best Predictor of Sustained Viral Response (SVR) in the Re-Treatment of
Previous Interferon-α/Ribavirin Non-Responders (NR): Results from the
EPIC3 Program (updated November 1,
2006)
o 1137. Comparison of a 24 -week standard combination
therapy with PEG-IFN-α2a/Ribavirin with a 12-week monotherapy with
PEG-IFN-α2a followed by a 12 week standard combination with
Peg-IFN-α2a/Ribavirin in Hepatitis C infected patients with genotype 2 or
3 (updated
October 31, 2006)
o Pegasys - Cirrhosis
§
330. Treatment of Cirrhotic Patients with HCV Referred for
Liver Transplantation Using an Escalating Dose Regimen of Pegylated Interferon
Alpha-2a and Ribavirin (updated October 28, 2006)
o Pegasys - Side effects
·
Peg-Intron
o 338. Pegylated interferon alfa 2 b + ribavirin are
equally efficacious and well tolerated in patients >65 years old in
comparison to other age groups: Subanalysis of a
randomized, controlled study (WIN-R Trial) (updated October 28,
2006)
o 339. A prospective, multicenter,
observational study on compliance with viral hepatitis C treatments (CHEOBS
study) (updated November 8, 2006)
o 343. Improved Virologic Response Rates With Treatment
Extension To 72 Weeks Of Peginterferon Alfa-2B Plus Weight-Based Ribavirin In A
Difficult-To-Treat Population Of Genotype 1-Infected Slow Responders
(updated
October 28, 2006)
o 349. Prospective Analysis of Sustained Virologic
Response (SVR) to Peg-interferon (PEG IFN) Alfa-2b and Ribavirin Treatment in
Asian and Hispanic Patients with Chronic Hepatitis C: Results from the WIN-R
Trial (updated October 28, 2006)
o 358. An Interim Analysis of the Canadian POWeR Program (Peginterferon alfa-2b Prospective Optimal
Weight-Based Dosing Response): Consistent SVR Rates Across All Weight
Categories (updated October 28, 2006)
o 369. Response to Peginterferon Alfa-2b and Ribavirin
for Chronic Hepatitis C in Patients with Body Weight >125 kg: Results from
the WIN-R Trial (updated October 28, 2006)
o 372. Economic Evaluation of Individualized versus
Standard Treatment Approach for Patients with Chronic Hepatitis C Virus
Genotype-1 (G1) Low Viral Load (LVL) Using Peginterferon Alpha-2b Plus
Ribavirin in the United Kingdom (updated November 8, 2006)
o 383. Standard and Pegylated Interferon alfa-2b plus
Ribavirin as initial treatment for HCV genotype 2 chronic hepatitis: analysis
of a large single center cohort. (updated October 28, 2006)
o 384. HCV-RNA in the fourth week as a predictive factor
of sustained virological response (SVR) in genotype 1 hepatitis C patients
treated with Peg-Interferon-α2b(PEG-IFN-α2b)and Ribavirin (updated October 28,
2006)
o 394. Treatment with Peginterferon alfa 2b and Ribavirin
of Chronic Hepatitis C Patients on Substitution Therapy and Outcome in the
Clinical Setting in Germany (updated November 8, 2006)
o 404. Pegylated Interferon alfa-2b Plus Ribavirin in
Patients With Genotype 1 Chronic Hepatitis C With a Slow Virologic Response: An
Early Enrollers Analysis of the SUCCESS Study (updated October 28,
2006)
o 778. Sustained Viral Response Using Peg IFN alfa-2b
Plus Ribavirin in Patients with Recurrent Hepatitis C after Liver
Transplantation (updated November 8, 2006)
o 1132. Risk Factors for Relapse in Genotype 3 High Viral
Load Patients with Hepatitis C In the WIN-R Trial (updated November 1,
2006)
o 1145. Long-term Low Dose Treatment with Pegylated
Interferon alpha 2b leads to a significant Reduction in Fibrosis and
Inflammatory Score in Chronic Hepatitis C Nonresponder
Patients with Fibrosis or Cirrhosis (updated November 3, 2006)
·
Prisons
o 258. Treatment of hepatitis C (HCV) in prison settings is
cost-effective: mathematical modeling of epidemiology, disease outcomes and
cost-effectiveness (updated October 28, 2006)
o 345. HCV Treatment Response Rates in an Incarcerated
Population-Influence of Race, Compliance and Pegylated Interferon (updated November 3,
2006)
·
Race
o LB23. Rapid and Early Virologic Responses to
Peginterferon Alfa-2a plus Ribavirin in Treatment-Naïve Latino vs non-Latino Caucasians Infected with HCV Genotype 1: the
LATINO Study (updated November 2, 2006)
·
Side effects
o 344. Efficacy and tolerability of citalopram
in interferon-induced depression: a randomized, placebo-controlled double-blind
study on the antidepressant treatment in HCV patients with antiviral therapy
(updated
November 1, 2006)
o 379. A Randomized Double-Blind Placebo-Controlled Trial
of Paroxetine to Prevent Interferon-α-Induced
Depression in Patients with Hepatitis C (updated October 28,
2006)